Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Tomoyuki Kashima,1 Hirotaka Itakura,1,2 Hideo Akiyama,1 Shoji Kishi11Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Gunma, Japan; 2Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Gunma, JapanAbstract: Rebamipide was initially developed and approved...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kashima T, Itakura H, Akiyama H, Kishi S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0476d7810ae346dc877d11c0e16a3793
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0476d7810ae346dc877d11c0e16a3793
record_format	dspace
spelling	oai:doaj.org-article:0476d7810ae346dc877d11c0e16a37932021-12-02T02:47:17ZRebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal1177-5483https://doaj.org/article/0476d7810ae346dc877d11c0e16a37932014-05-01T00:00:00Zhttp://www.dovepress.com/rebamipide-ophthalmic-suspension-for-the-treatment-of-dry-eye-syndrome-a17080https://doaj.org/toc/1177-5483 Tomoyuki Kashima,1 Hirotaka Itakura,1,2 Hideo Akiyama,1 Shoji Kishi11Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Gunma, Japan; 2Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Gunma, JapanAbstract: Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan.Keywords: quinolinone derivative, tear deficiency, ocular surface disorder, mucin secretion, MucostaKashima TItakura HAkiyama HKishi SDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1003-1010 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Kashima T Itakura H Akiyama H Kishi S Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
description	Tomoyuki Kashima,1 Hirotaka Itakura,1,2 Hideo Akiyama,1 Shoji Kishi11Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Gunma, Japan; 2Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Gunma, JapanAbstract: Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan.Keywords: quinolinone derivative, tear deficiency, ocular surface disorder, mucin secretion, Mucosta
format	article
author	Kashima T Itakura H Akiyama H Kishi S
author_facet	Kashima T Itakura H Akiyama H Kishi S
author_sort	Kashima T
title	Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
title_short	Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
title_full	Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
title_fullStr	Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
title_full_unstemmed	Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
title_sort	rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/0476d7810ae346dc877d11c0e16a3793
work_keys_str_mv	AT kashimat rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT itakurah rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT akiyamah rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT kishis rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal
_version_	1718402142615633920

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Ejemplares similares